Guru Fundamental Report for JNJ

Validea's guru fundamental report assigns Johnson & Johnson (JNJ) a 77% rating under Partha Mohanram's P/B Growth Investor model, which seeks low book-to-market stocks with sustained future growth. While JNJ, a large-cap biotech/drug stock, passed most of the model's criteria, including strong asset returns and cash flow, it notably failed on advertising and R&D to assets, placing it just below the 80% threshold for investor interest. This assessment provides a specific academic-backed view on JNJ's growth profile from a model designed to identify outperforming growth stocks.

Analysis

According to a Validea fundamental report, Johnson & Johnson (JNJ) scores a 77% based on Partha Mohanram's P/B Growth Investor model, a framework designed to identify outperforming growth stocks among low book-to-market companies. This score places JNJ just below the 80% threshold that typically signals investor interest from this specific strategy. The analysis reveals a fundamentally sound company, as JNJ passed key criteria related to its book-to-market ratio, return on assets (ROA), cash flow from operations to assets, and stability in both ROA and sales variance. However, the model flagged weaknesses in two areas critical for future growth: JNJ failed the tests for Advertising to Assets and Research and Development to Assets. This suggests that while JNJ demonstrates strong current profitability and operational efficiency, its investment levels in brand building and innovation may not meet the aggressive growth profile sought by the Mohanram model.

Key Decisions for Investors

• Investors strictly following quantitative growth models like Mohanram's may consider JNJ a hold rather than a buy, as its 77% score indicates it is a borderline candidate that fails to meet key growth-investment criteria.
• The failure on Research and Development to Assets metrics is a significant flag for a biotech and drug company, warranting closer scrutiny of JNJ's innovation pipeline and R&D productivity relative to its large asset base.
• Value-oriented or GARP investors might find the strong performance on cash flow, return on assets, and stability metrics attractive, viewing the model's growth-specific concerns as less critical than the company's underlying financial health.
• Consider monitoring JNJ's future capital allocation, as a strategic increase in R&D and advertising spending could improve its standing within this growth framework and signal a more aggressive pursuit of future expansion.